The following email was sent to members of UCSD Moores Cancer Center on Saturday, June 3. The email addresses The Cancer Letter story focused on the resignation of the center’s director Joe Califano and on problems at the institution (The Cancer Letter, June 2, 2023).
The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.
